For help on how to get the results you want, see our search tips.
1850 results
-
List item
Human medicine European public assessment report (EPAR): Imatinib Koanaa (new)
imatinib mesilate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Hypereosinophilic Syndrome; Dermatofibrosarcoma; Gastrointestinal Stromal Tumors
Date of authorisation: 22/09/2021,
, Authorised, Last updated: 01/10/2021
-
List item
Human medicine European public assessment report (EPAR): Ryeqo
Relugolix, norethisterone acetate, estradiol hemihydrate, Leiomyoma
Date of authorisation: 16/07/2021,
, Revision: 1, Authorised, Last updated: 13/09/2021
-
List item
Human medicine European public assessment report (EPAR): Bimzelx
Bimekizumab, Psoriasis
Date of authorisation: 20/08/2021,, Authorised, Last updated: 24/08/2021
-
List item
Human medicine European public assessment report (EPAR): Byooviz
ranibizumab, Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Myopia, Degenerative
Date of authorisation: 18/08/2021,, 
, Authorised, Last updated: 08/09/2021
-
List item
Human medicine European public assessment report (EPAR): Evrenzo
Roxadustat, Anemia; Kidney Failure, Chronic
Date of authorisation: 18/08/2021,, Authorised, Last updated: 24/08/2021
-
List item
Human medicine European public assessment report (EPAR): Voxzogo
Vosoritide, Achondroplasia
Date of authorisation: 26/08/2021,, 
, Authorised, Last updated: 09/09/2021
-
List item
Human medicine European public assessment report (EPAR): Minjuvi (updated)
Tafasitamab, Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 26/08/2021,, , 
, Revision: 1, Authorised, Last updated: 05/10/2021
-
List item
Human medicine European public assessment report (EPAR): Abiraterone Mylan
abiraterone acetate, Prostatic Neoplasms
Date of authorisation: 20/08/2021,, Authorised, Last updated: 26/08/2021
-
List item
Human medicine European public assessment report (EPAR): Abecma (updated)
idecabtagene vicleucel, Multiple Myeloma; Neoplasms; Cancer; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Infectious Mononucleosis; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases
Date of authorisation: 18/08/2021,, , , Revision: 01, Authorised, Last updated: 12/10/2021
-
List item
Veterinary medicine European public assessment report (EPAR): Fatrovax RHD (updated)
Rabbit hemorrhagic disease virus 2 VP1AB, Rabbit hemorrhagic disease virus VP1A, Rabbits
Date of authorisation: 16/08/2021, Authorised, Last updated: 12/10/2021 -
List item
Veterinary medicine European public assessment report (EPAR): Tessie (updated)
Tasipimidine sulfate, Dogs
Date of authorisation: 16/08/2021, Authorised, Last updated: 13/10/2021 -
List item
Human medicine European public assessment report (EPAR): Klisyri
tirbanibulin, Keratosis, Actinic
Date of authorisation: 16/07/2021,, Authorised, Last updated: 21/07/2021
-
List item
Human medicine European public assessment report (EPAR): Imcivree
Setmelanotide, Obesity
Date of authorisation: 16/07/2021,, , Authorised, Last updated: 22/07/2021
-
List item
Human medicine European public assessment report (EPAR): Verquvo
Vericiguat, Heart Failure
Date of authorisation: 16/07/2021,, Authorised, Last updated: 27/07/2021
-
List item
Human medicine European public assessment report (EPAR): Skysona
elivaldogene autotemcel, Adrenoleukodystrophy
Date of authorisation: 16/07/2021,, , Authorised, Last updated: 27/07/2021
-
List item
Human medicine European public assessment report (EPAR): Bylvay
Odevixibat, Cholestasis, Intrahepatic
Date of authorisation: 16/07/2021,
, , 
, Authorised, Last updated: 28/07/2021
-
List item
Human medicine European public assessment report (EPAR): Icatibant Accord
icatibant acetate, Angioedemas, Hereditary
Date of authorisation: 16/07/2021,, Authorised, Last updated: 06/09/2021
-
List item
Human medicine European public assessment report (EPAR): Ozawade (updated)
pitolisant,
Date of authorisation: 01/09/2021, Authorised, Last updated: 14/10/2021 -
List item
Human medicine European public assessment report (EPAR): Evkeeza
Evinacumab, Hypercholesterolemia
Date of authorisation: 17/06/2021,, , Authorised, Last updated: 21/04/2021
-
List item
Human medicine European public assessment report (EPAR): Celsunax
ioflupane (123i), Radionuclide Imaging; Dementia; Movement Disorders
Date of authorisation: 17/06/2021,, Authorised, Last updated: 02/07/2021
-
List item
Human medicine European public assessment report (EPAR): Jayempi
azathioprine, Graft Rejection
Date of authorisation: 21/06/2021, Authorised, Last updated: 23/06/2021 -
List item
Human medicine European public assessment report (EPAR): Adtralza
Tralokinumab,
Date of authorisation: 17/06/2021,, Authorised, Last updated: 19/08/2021
-
List item
Human medicine European public assessment report (EPAR): Onureg
azacitidine, Leukemia, Myeloid, Acute
Date of authorisation: 17/06/2021, Revision: 1, Authorised, Last updated: 06/09/2021 -
List item
Human medicine European public assessment report (EPAR): Enspryng
satralizumab, Neuromyelitis Optica
Date of authorisation: 24/06/2021,, Revision: 1, Authorised, Last updated: 15/09/2021
-
List item
Human medicine European public assessment report (EPAR): Koselugo (new)
Selumetinib sulfate, Neurofibromatosis 1
Date of authorisation: 17/06/2021,, , , Authorised, Last updated: 13/10/2021